Grail says about 400 patients incorrectly informed they may have cancer

Illumina Spinoff Grail Says Vendor Error Caused 400 Patients to Be Told They Have Cancer

A building on the Illumina Campus in University City. Reuters/Mike Blake Cancer test maker Grail said on Friday that its telemedicine vendor erroneously sent letters to about 400 patients suggesting they may have developed cancer. Grail’s flagship cancer detection blood test Galleri is designed to detect more than 50 types of cancer before symptoms appear. The company, owned by San Diego-based Illumina, said the letters were mistakenly sent by P…

Cancer test company says vendor mistakenly sent letters to 400 patients that they may have disease

Cancer test company Grail, Inc. said Friday its telemedicine vendor had mistakenly sent form letters to about 400 patients, telling them they may have cancer.  Grail, which is owned by San Diego-based biotechnology company Illumina, told Fox News Digital that all the patients were informed immediately of the mistake and it "was in no way related to or caused by an incorrect Galleri test result," Reuters reported.  The company’s Galleri blood tes…

Grail says about 400 patients incorrectly informed they may have cancer

Cancer test maker Grail Inc said on Friday that its telemedicine vendor erroneously sent letters to about 400 patients suggesting they may have developed cancer.

Grail says over 400 patients incorrectly informed they may have cancer

Grail’s flagship cancer detection blood test Galleri is designed to detect more than 50 types of cancer before symptoms appear

More than 400 Grail patients incorrectly told they may have cancer

Life assurance customers pause review relationship with early-detection biotech.

Around 400 Grail Patients Mistakenly Told They Might Have Cancer—Company Blames Vendor

The patients signed up to take Galleri, a prescription oncology detection test, and later received letters suggesting they had cancer.